{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:15:38Z","timestamp":1778580938589,"version":"3.51.4"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The dexamethasone suppression test (DST) is a key diagnostic tool for evaluating disorders of the hypothalamic\u2013pituitary\u2013adrenal (HPA) axis. Interpretation of DST results can be confounded by inadequate dexamethasone exposure due to pharmacokinetic variability or patient nonadherence. Simultaneous measurement of dexamethasone and cortisol by LC-MS\/MS improves diagnostic accuracy by distinguishing true biological nonsuppression from insufficient drug exposure and prevents analytical interferences observed with cortisol immunoassays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A commercially available CE-IVD LC-MS\/MS steroid panel (Chromsystems) was adapted for the simultaneous quantification of dexamethasone and cortisol in human plasma. The method was validated for linearity, accuracy, precision, selectivity, carry-over, matrix effects, and stability. Method comparison was performed using 26 clinical DST samples analyzed using immunoassay and external LC-MS testing. The proposed dexamethasone cutoff of 1.3 ng\/mL (3.3 nmol\/L) was evaluated in 62 patient samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The method demonstrated excellent linearity, with intra- and interassay accuracy and precision within \u00b115% for both analytes. No relevant carry-over or matrix effects were observed. Agreement with reference methods was 91% \u00b1 6% for cortisol and 95% \u00b1 7% for dexamethasone. Among the 62 DST samples, 48 showed appropriate suppression [cortisol &lt;18.12 ng\/mL (&lt;50 nmol\/L)] with dexamethasone levels above the cutoff. In contrast, 3 samples with insufficient suppression [cortisol &gt;48.6 ng\/mL (134.1 nmol\/L)] had subthreshold dexamethasone levels, whereas 11 samples showed elevated cortisol levels despite sufficient dexamethasone exposure, indicating possible HPA axis dysfunction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The proposed rapid and robust LC-MS\/MS method enables reliable, simultaneous quantification of dexamethasone and cortisol. The assay supports accurate DST interpretation by identifying cases of pharmacokinetic variance or nonadherence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001389","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T05:00:09Z","timestamp":1759208409000},"page":"307-313","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Simultaneous Quantification of Dexamethasone and Cortisol for the Dexamethasone Suppression Test Using LC-MS\/MS: Adaptation of a Commercial CE-IVD Steroid Assay"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-1617-6524","authenticated-orcid":false,"given":"Regula","family":"Steiner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3111-0750","authenticated-orcid":false,"given":"Marc","family":"Luginb\u00fchl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"R1-20260508","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4103\/1817-1737.65040","article-title":"Genomic and non-genomic actions of glucocorticoids in asthma","volume":"5","author":"Alangari","year":"2010","journal-title":"Ann Thorac Med"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.3390\/ijms18102201","article-title":"Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis","volume":"18","author":"Paragliola","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.psyneuen.2006.12.009","article-title":"Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder","volume":"32","author":"de Kloet","year":"2007","journal-title":"Psychoneuroendocrinology"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.clinthera.2011.10.006","article-title":"Pharmacokinetics, pharmacodynamics, and comparative bioavailability of single, oral 2-mg doses of dexamethasone liquid and tablet formulations: a randomized, controlled, crossover study in healthy adult volunteers","volume":"33","author":"Queckenberg","year":"2011","journal-title":"Clin Ther"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.addr.2019.02.004","article-title":"Chronopharmacology of glucocorticoids","volume":"151\u2013152","author":"Scherholz","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1177\/0091270003258651","article-title":"Dose equivalency evaluation of major corticosteroids: pharmacokinetics and cell trafficking and cortisol dynamics","volume":"43","author":"Mager","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0006-3223(02)01357-4","article-title":"The cortisol and glucocorticoid receptor response to low dose dexamethasone administration in aging combat veterans and holocaust survivors with and without posttraumatic stress disorder","volume":"52","author":"Yehuda","year":"2002","journal-title":"Biol Psychiatry"},{"key":"R8-20260508","first-page":"565","article-title":"The impact of dexamethasone pharmacokinetics on the DST: a review","volume":"27","author":"Guthrie","year":"1991","journal-title":"Psychopharmacol Bull"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1590\/S0004-27302007000800006","article-title":"Pitfalls in the diagnosis of Cushing's syndrome","volume":"51","author":"Vilar","year":"2007","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3390\/molecules28010248","article-title":"Simultaneous measurement of cortisol, cortisone, dexamethasone and additional exogenous corticosteroids by rapid and sensitive LC\u2013MS\/MS analysis","volume":"28","author":"Ponzetto","year":"2022","journal-title":"Molecules"},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/ijem.ijem_482_23","article-title":"A cross-sectional study on comparison of serum cortisol concentration measured by chemiluminescent immunoassay in four different automated analyzers in a variety of adrenal disorders","volume":"29","author":"Agrawal","year":"2025","journal-title":"Indian J Endocrinol Metab"},{"key":"R12-20260508","article-title":"ICH harmonised guideline M10\u2013Bioanalytical method validation and study sample analysis","year":"2023"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-17-0078","article-title":"Simultaneous assay of cortisol and dexamethasone improved diagnostic accuracy of the dexamethasone suppression test","volume":"176","author":"Ueland","year":"2017","journal-title":"Eur J Endocrinol"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001389","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:40:58Z","timestamp":1778578858000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001389","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"2025-05-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}